What’s new about pegunigalsidase alfa for Fabry?
This review covers plant-cell PEGylated α-Gal A ERT: Gb3 clearance, phase 3 programs, and BALANCE eGFR slope difference −0.36 mL/min/1.73 m²/year vs agalsidase beta within non-inferiority bounds.
Source
Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease
Study at a glance
- Design
- Other — Mini-review of pegunigalsidase alfa pharmacology and phase 1–3 Fabry ERT trials
- N
- N=3 · Focus on three phase 3 programs: BRIDGE, BRIGHT, BALANCE
- Population
- Patients with Fabry disease in reviewed clinical trials of pegunigalsidase alfa
- Outcome
- Renal function (eGFR slope), Gb3 clearance, safety/tolerability vs prior ERTs
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
What’s new about pegunigalsidase alfa for Fabry?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
BALANCE intergroup median eGFR slope difference −0.36.
an intention-to-treat analysis of the eGFR decline over 2 years showed that the intergroup difference [95%confidence interval] in the median slope was −0.36 mL/min/1.73 m 2 /year [−2.44; 1.73].
97% of BALANCE completers continued pegunigalsidase alfa.
97% of the study participants who completed the BALANCE clinical trial decided to continue or start treatment with pegunigalsidase alfa
What they did
Summarized pharmacology and phase 1/2 plus BRIDGE/BRIGHT/BALANCE evidence, including BALANCE ITT eGFR slopes and extension uptake.
What they found
Enhanced stability/half-life via PEGylation; favorable efficacy/safety signals with caveats for uncontrolled BRIDGE/BRIGHT; BALANCE CI above −3 and including zero; 97% BALANCE completers continued therapy.
The limits
What it doesn't show
Review does not replace reading primary trial protocols; BRIDGE/BRIGHT lack controls.
Key terms
- Fabry disease
- X-linked GLA deficiency with multi-organ Gb3 storage.
- Pegunigalsidase alfa
- PEGylated recombinant α-galactosidase A ERT.
- PEGylation
- PEG modification prolonging half-life/reducing immunogenicity.
- BALANCE trial
- Pivotal phase 3 vs agalsidase beta on eGFR slope.
- eGFR slope
- Rate of kidney function change used as key endpoint.
- Enzyme replacement therapy (ERT)
- Infused enzyme to replace deficient α-Gal A.
Flashcards
0 of 8 answers reviewed
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
Fabry gene:
Common questions
Phase 3 names?
BRIDGE, BRIGHT, BALANCE.
BALANCE eGFR slope difference?
−0.36 mL/min/1.73 m²/year.
Non-inferiority bound referenced?
−3 mL/min/1.73 m²/year.
BALANCE completers continuing drug?
97%.
More on Gene expression